Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2016

01.09.2016 | original report

Healthcare resource utilization and G‑CSF use in patients with solid tumors or hematological malignancies hospitalized for febrile neutropenia in Bulgaria, Czech Republic and Slovakia

verfasst von: Georgi Mihaylov, Zhasmina Mihaylova, Lubos Drgona, Andrea Cipkova, Jan Novak, Roumyana Petrova

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

Febrile neutropenia (FN) is a common side effect of chemotherapy that frequently necessitates hospitalization and healthcare resource utilization (HCRU), but is poorly studied in Eastern European countries. We investigated HCRU and granulocyte colony-stimulating factor (G-CSF) use in patients hospitalized for FN in Bulgaria, Czech Republic, and Slovakia.

Patients and methods

This was a multicenter retrospective cohort study. Eligible patients were ≥18 years old, had received chemotherapy for solid tumors or hematological malignancies of any stage, and had been hospitalized for FN. The primary objective was to evaluate FN-related HCRU; secondary objectives included the description of chemotherapy treatment patterns and G‑CSF use. Data were analyzed by participating country.

Results

Data of 156 patients from Bulgaria and 79 patients each from the Czech Republic and Slovakia were analyzed. The most frequent solid tumors were breast (n = 28) and testicular cancer (n = 13), and the most common hematological malignancies were non-Hodgkin B‑cell lymphoma (n = 51) and acute myeloid leukemia (n = 35). In general, G‑CSF was used to treat FN rather than as prophylaxis. Most patients had a single FN episode, predominantly in cycle 1. The mean duration of FN-related hospitalization was 7–9 days, with longer stays in patients with hematological malignancies.

Conclusions

Results indicate considerable FN-related HCRU in all countries. Frequent lack of G‑CSF primary prophylaxis was observed, particularly in Slovakia.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228–37. CrossRefPubMed Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228–37. CrossRefPubMed
2.
Zurück zum Zitat Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29–35. CrossRefPubMed Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29–35. CrossRefPubMed
3.
Zurück zum Zitat Holmes FA, Jones SE, O’Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13(6):903–9. CrossRefPubMed Holmes FA, Jones SE, O’Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13(6):903–9. CrossRefPubMed
4.
Zurück zum Zitat Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20(3):727–31. CrossRefPubMed Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20(3):727–31. CrossRefPubMed
5.
Zurück zum Zitat Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32. CrossRefPubMed Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32. CrossRefPubMed
6.
Zurück zum Zitat Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–66. CrossRefPubMed Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–66. CrossRefPubMed
7.
Zurück zum Zitat Hirsch BR, Lyman GH. Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. Pharmacoeconomics. 2012;30(6):497–511. CrossRefPubMed Hirsch BR, Lyman GH. Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. Pharmacoeconomics. 2012;30(6):497–511. CrossRefPubMed
8.
Zurück zum Zitat Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study. Exp Ther Med. 2011;2(5):859–66. PubMedPubMedCentral Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study. Exp Ther Med. 2011;2(5):859–66. PubMedPubMedCentral
9.
Zurück zum Zitat Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24):4524–31. CrossRefPubMed Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24):4524–31. CrossRefPubMed
10.
Zurück zum Zitat Weycker D, Danel A, Bendall K, et al. Cost of chemotherapy-induced febrile neutropenia treated in inpatient, outpatient, and home care settings among adults with non-Hodgkin’s lymphoma in European clinical practice. Blood. 2011;118:4200, ASH Annual Meeting Abstracts. Weycker D, Danel A, Bendall K, et al. Cost of chemotherapy-induced febrile neutropenia treated in inpatient, outpatient, and home care settings among adults with non-Hodgkin’s lymphoma in European clinical practice. Blood. 2011;118:4200, ASH Annual Meeting Abstracts.
11.
Zurück zum Zitat Weycker D, Barron R, Kartashov A, et al. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract. 2014;20(3):190–8. CrossRefPubMed Weycker D, Barron R, Kartashov A, et al. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract. 2014;20(3):190–8. CrossRefPubMed
12.
Zurück zum Zitat Saramago P, Andreozzi V, Ferreira JM, et al. Modelling the direct costs of chemotherapy-induced neutropenia treatment in Portuguese hospitals clinical practice. J Clin Oncol. 2007;25(18S):17081, ASCO Annual Meeting Proceedings (Post-Meeting Edition), June 20 Supplement. Saramago P, Andreozzi V, Ferreira JM, et al. Modelling the direct costs of chemotherapy-induced neutropenia treatment in Portuguese hospitals clinical practice. J Clin Oncol. 2007;25(18S):17081, ASCO Annual Meeting Proceedings (Post-Meeting Edition), June 20 Supplement.
13.
Zurück zum Zitat Mayordomo JI, Lopez A, Vinolas N, et al. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin. 2009;25(10):2533–42. CrossRefPubMed Mayordomo JI, Lopez A, Vinolas N, et al. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin. 2009;25(10):2533–42. CrossRefPubMed
14.
Zurück zum Zitat Ihbe-Heffinger A, Paessens BJ, von Schilling C, et al. Management of febrile neutropenia – a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer. Onkologie. 2011;34(5):241–6. CrossRefPubMed Ihbe-Heffinger A, Paessens BJ, von Schilling C, et al. Management of febrile neutropenia – a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer. Onkologie. 2011;34(5):241–6. CrossRefPubMed
15.
Zurück zum Zitat Moeremans K, Caekelbergh K, Spaepen E. et al. Economic aspects and drivers of febrile neutropenia in cancer – a multicentre retrospective analysis in Belgium. ISPOR 8th Annual European Congress, Florence. 2005. Moeremans K, Caekelbergh K, Spaepen E. et al. Economic aspects and drivers of febrile neutropenia in cancer – a multicentre retrospective analysis in Belgium. ISPOR 8th Annual European Congress, Florence. 2005.
16.
Zurück zum Zitat Liu Z, Doan QV, Malin J, et al. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl Health Econ Health Policy. 2009;7(3):193–205. CrossRefPubMed Liu Z, Doan QV, Malin J, et al. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl Health Econ Health Policy. 2009;7(3):193–205. CrossRefPubMed
17.
Zurück zum Zitat Vainchtock A, Cohen-Nizard S, Durand-Zaleski I. Analysis of public and private hospital databases (PMSI) 2010/2011 to estimate the frequency and associated costs for febrile neutropenia in france. ISPOR 16th Annual European Congress, Dublin. 2013. Vainchtock A, Cohen-Nizard S, Durand-Zaleski I. Analysis of public and private hospital databases (PMSI) 2010/2011 to estimate the frequency and associated costs for febrile neutropenia in france. ISPOR 16th Annual European Congress, Dublin. 2013.
18.
Zurück zum Zitat Mattli R, Pletscher M, Eichler K. et al. Inpatient hospital costs of febrile neutropenia as a consequence of chemotherapy for breast cancer and Non-Hodgkin Lymphoma in Switzerland. ISPOR 16th Annual European Congress, Dublin. 2013. Mattli R, Pletscher M, Eichler K. et al. Inpatient hospital costs of febrile neutropenia as a consequence of chemotherapy for breast cancer and Non-Hodgkin Lymphoma in Switzerland. ISPOR 16th Annual European Congress, Dublin. 2013.
19.
Zurück zum Zitat Liou SY, Stephens JM, Carpiuc KT, et al. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig. 2007;27(6):381–96. CrossRefPubMed Liou SY, Stephens JM, Carpiuc KT, et al. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig. 2007;27(6):381–96. CrossRefPubMed
20.
Zurück zum Zitat Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–67. CrossRefPubMed Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–67. CrossRefPubMed
21.
Zurück zum Zitat Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916–24. CrossRefPubMed Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916–24. CrossRefPubMed
22.
Zurück zum Zitat Kuderer NM. Meta-analysis of randomized controlled trials of granulocyte colony-stimulating factor prophylaxis in adult cancer patients receiving chemotherapy. Cancer Treat Res. 2011;157:127–43. CrossRefPubMed Kuderer NM. Meta-analysis of randomized controlled trials of granulocyte colony-stimulating factor prophylaxis in adult cancer patients receiving chemotherapy. Cancer Treat Res. 2011;157:127–43. CrossRefPubMed
23.
Zurück zum Zitat Crawford J, Glaspy JA, Stoller RG, et al. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther. 2005;3(1):36–46. CrossRefPubMed Crawford J, Glaspy JA, Stoller RG, et al. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther. 2005;3(1):36–46. CrossRefPubMed
24.
Zurück zum Zitat Fiegl M, Steger GG, Studnicka M, et al. Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study. Curr Med Res Opin. 2013;29(5):505–15. CrossRefPubMed Fiegl M, Steger GG, Studnicka M, et al. Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study. Curr Med Res Opin. 2013;29(5):505–15. CrossRefPubMed
25.
Zurück zum Zitat Maenpaa J, Varthalitis I, Erdkamp F, et al. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer – further observations from the IMPACT solid study. Breast. 2016;25:27–33. CrossRefPubMed Maenpaa J, Varthalitis I, Erdkamp F, et al. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer – further observations from the IMPACT solid study. Breast. 2016;25:27–33. CrossRefPubMed
Metadaten
Titel
Healthcare resource utilization and G‑CSF use in patients with solid tumors or hematological malignancies hospitalized for febrile neutropenia in Bulgaria, Czech Republic and Slovakia
verfasst von
Georgi Mihaylov
Zhasmina Mihaylova
Lubos Drgona
Andrea Cipkova
Jan Novak
Roumyana Petrova
Publikationsdatum
01.09.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0279-z